On March 14, 2007, the French competition authority (le Conseil de la Concurrence) imposed a €10 million fine on GSK’s French division for hindering the use of generic drugs in hospitals with a “predatory” pricing policy. The authority considered that in 1999 and 2000 GSK had sold an injectable antibiotic at less than cost price to slow down the entry of generic alternatives into the hospital market. This is the first case in France penalizing predatory pricing.